Abstract
Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alkynes
-
Anti-HIV Agents / administration & dosage*
-
Antiretroviral Therapy, Highly Active / methods
-
Antitubercular Agents / administration & dosage
-
Benzoxazines / administration & dosage*
-
Cyclopropanes
-
Female
-
HIV / isolation & purification*
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
Humans
-
Male
-
Tuberculosis / complications
-
Viral Load*
-
Viremia*
Substances
-
Alkynes
-
Anti-HIV Agents
-
Antitubercular Agents
-
Benzoxazines
-
Cyclopropanes
-
efavirenz